Which drug lowers cholesterol better? new study compares alirocumab and inclisiran
NCT ID NCT07615166
First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 3 times
Summary
This study looks at two medicines, alirocumab and inclisiran, that help lower bad cholesterol (LDL-C) in people with heart disease. Researchers will use real-world data from about 124 patients to see which drug reduces cholesterol more over time. The goal is to understand how these treatments compare in everyday medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
996 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Jun 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults (\>= 18 years) initiating alirocumab 150 mg or inclisiran among adults eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) -targeting therapy in routine practice: from January 2016 to July 2024.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants initiating alirocumab 150 mg or inclisiran. * Participants with at least once LDL-C measurement during 365 days before index. * Participants who continuously enrolled in medical and pharmacy benefits for at least 365 days pre index. Exclusion Criteria: * Participants with unknown sex, geographic region, or insurance type, and age \< 18 years at index. * Participants with exposure to evolocumab before index. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanofi
Bridgewater, New Jersey, 08807, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Vitamin B3 supplement put to the test against psoriasis inflammation
- Can calming inflammation shield the heart?
- Your smartwatch may predict a heart attack days before it happens
- Could an arthritis drug shield heart and kidneys in metabolic syndrome?
- Heart drug showdown: which statin spares your blood sugar?
- 3,000 volunteers to reveal hidden heart risks in qatar